Journals LibraryNHS NIHR - National Institute for Health Research
HTA - 07/03/01
Early high dose lipid-lowering therapy to avoid cardiac events
Project title: Early high dose lipid-lowering therapy to avoid cardiac events
Call to action: 07/03 Early high dose lipid-lowering therapy to avoid cardiac events
Research type: Evidence Synthesis
Contractor: The University of Sheffield
Co-investigators: Mr Abdullah Pandor.
Started: January 2008 | Status: Published July 2009
Study found that rosuvastatin 40 mg/day is the most effective treatment in terms of lowering low-density lipoprotein cholesterol and is the optimal treatment for individuals with a recent history of acute coronary syndrome using a threshold of £20,000 per QALY. However, if the cost of atorvastatin decreases when the patent ends in 2011, atorvastatin 80 mg/day will become the most cost-effective treatment for all thresholds
Links to project documentation
The links and documents below are related to this research and are added as and when they are produced over the life of the project. The information is provided by the researchers and some may have undergone varying editorial, production and publication models, which differ to NIHR Journals Library reports. Links are to both internal (NIHR) and external websites – the NIHR is not responsible for the content of external websites.